M1 Kliniken Toekomstige groei
Future criteriumcontroles 2/6
M1 Kliniken zal naar verwachting groeien in winst en omzet met respectievelijk 17.5% en 8.2% per jaar. De winst per aandeel zal naar verwachting groeien met 15.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 18.7% zijn.
Belangrijke informatie
17.5%
Groei van de winst
15.8%
Groei van de winst per aandeel
| Healthcare winstgroei | 23.1% |
| Inkomstengroei | 8.2% |
| Toekomstig rendement op eigen vermogen | 18.7% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 06 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Does M1 Kliniken (ETR:M12) Have A Healthy Balance Sheet?
Oct 15
Earnings Not Telling The Story For M1 Kliniken AG (ETR:M12) After Shares Rise 27%
Sep 24Why We're Not Concerned Yet About M1 Kliniken AG's (ETR:M12) 27% Share Price Plunge
Aug 03Additional Considerations Required While Assessing M1 Kliniken's (ETR:M12) Strong Earnings
Jun 06M1 Kliniken AG (ETR:M12) Looks Just Right With A 53% Price Jump
May 29M1 Kliniken (ETR:M12) Might Be Having Difficulty Using Its Capital Effectively
May 03At €14.40, Is It Time To Put M1 Kliniken AG (ETR:M12) On Your Watch List?
Mar 07Why Investors Shouldn't Be Surprised By M1 Kliniken AG's (ETR:M12) 25% Share Price Surge
Feb 18Is M1 Kliniken AG (ETR:M12) Trading At A 46% Discount?
Feb 17An Intrinsic Calculation For M1 Kliniken AG (ETR:M12) Suggests It's 27% Undervalued
Sep 01Should You Think About Buying M1 Kliniken AG (ETR:M12) Now?
Jun 01The Returns On Capital At M1 Kliniken (ETR:M12) Don't Inspire Confidence
Mar 25Investors Could Be Concerned With M1 Kliniken's (ETR:M12) Returns On Capital
Dec 17Is Now The Time To Look At Buying M1 Kliniken AG (ETR:M12)?
Nov 02Time To Worry? Analysts Are Downgrading Their M1 Kliniken AG (ETR:M12) Outlook
May 26Analysts Have Lowered Expectations For M1 Kliniken AG (ETR:M12) After Its Latest Results
May 25Here's What's Concerning About M1 Kliniken's (ETR:M12) Returns On Capital
Dec 06There Are Reasons To Feel Uneasy About M1 Kliniken's (ETR:M12) Returns On Capital
May 22Here's What M1 Kliniken AG's (ETR:M12) Shareholder Ownership Structure Looks Like
Mar 19We're Watching These Trends At M1 Kliniken (ETR:M12)
Feb 21M1 Kliniken (ETR:M12) Has Gifted Shareholders With A Fantastic 106% Total Return On Their Investment
Feb 03
Are Dividend Investors Getting More Than They Bargained For With M1 Kliniken AG's (ETR:M12) Dividend?
Jan 16M1 Kliniken AG's (ETR:M12) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Dec 29Here's Why We Don't Think M1 Kliniken's (ETR:M12) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 14When Should You Buy M1 Kliniken AG (ETR:M12)?
Nov 28Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 405 | 24 | 25 | 29 | 2 |
| 12/31/2025 | 372 | 18 | 20 | 24 | 2 |
| 12/31/2024 | 341 | 14 | 17 | 22 | 2 |
| 6/30/2024 | 333 | 17 | 19 | 20 | N/A |
| 3/31/2024 | 325 | 14 | 13 | 14 | N/A |
| 12/31/2023 | 316 | 10 | 7 | 8 | N/A |
| 9/30/2023 | 307 | 8 | 9 | 10 | N/A |
| 6/30/2023 | 297 | 6 | 11 | 13 | N/A |
| 3/31/2023 | 291 | 5 | 15 | 17 | N/A |
| 12/31/2022 | 285 | 4 | 19 | 21 | N/A |
| 9/30/2022 | 287 | 6 | 20 | 22 | N/A |
| 6/30/2022 | 288 | 7 | 21 | 22 | N/A |
| 3/31/2022 | 302 | 8 | 18 | 19 | N/A |
| 12/31/2021 | 315 | 9 | 14 | 16 | N/A |
| 9/30/2021 | 304 | 9 | N/A | N/A | N/A |
| 6/30/2021 | 293 | 10 | 14 | 15 | N/A |
| 3/31/2021 | 226 | 8 | 11 | 12 | N/A |
| 12/31/2020 | 160 | 7 | 8 | 10 | N/A |
| 9/30/2020 | 118 | 7 | N/A | N/A | N/A |
| 6/30/2020 | 76 | 6 | -9 | -8 | N/A |
| 3/31/2020 | 77 | 8 | -8 | -7 | N/A |
| 12/31/2019 | 77 | 10 | -7 | -5 | N/A |
| 9/30/2019 | 73 | 8 | -4 | -2 | N/A |
| 6/30/2019 | 69 | 7 | 0 | 1 | N/A |
| 3/31/2019 | 67 | 7 | 0 | 2 | N/A |
| 12/31/2018 | 65 | 7 | 1 | 3 | N/A |
| 9/30/2018 | 60 | 6 | -1 | 1 | N/A |
| 6/30/2018 | 54 | 5 | -2 | 0 | N/A |
| 3/31/2018 | 51 | 6 | N/A | 1 | N/A |
| 12/31/2017 | 47 | 6 | N/A | 2 | N/A |
| 9/30/2017 | 43 | 6 | N/A | 5 | N/A |
| 6/30/2017 | 40 | 6 | N/A | 8 | N/A |
| 3/31/2017 | 38 | 5 | N/A | 8 | N/A |
| 12/31/2016 | 36 | 5 | N/A | 8 | N/A |
| 9/30/2016 | 40 | 7 | N/A | 7 | N/A |
| 6/30/2016 | 43 | 10 | N/A | 5 | N/A |
| 3/31/2016 | 39 | 8 | N/A | 3 | N/A |
| 12/31/2015 | 35 | 7 | N/A | 0 | N/A |
| 12/31/2014 | 23 | 5 | N/A | 1 | N/A |
| 12/31/2013 | 6 | 0 | N/A | -5 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei M12 ( 17.5% per jaar) ligt boven de spaarquote ( 0.8% ).
Winst versus markt: De winst van M12 ( 17.5% per jaar) zal naar verwachting langzamer groeien dan de markt German ( 20.2% per jaar).
Hoge groeiwinsten: De winst van M12 zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van M12 ( 8.2% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.5% per jaar).
Hoge groei-inkomsten: De omzet van M12 ( 8.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen M12 zal naar verwachting over 3 jaar laag zijn ( 18.7 %).